This brand name is authorized in United States.
The drug WINREVAIR contains one active pharmaceutical ingredient (API):
1
|
UNII
0QI90BTJ37 - SOTATERCEPT
|
|
Sotatercept is an activin signalling inhibitor with high selectivity for Activin-A, a dimeric glycoprotein which belongs to the transforming growth factor-β (TGF-β) superfamily of ligands. Activin-A binds to the activin receptor type IIA (ActRIIA) regulating key signalling for inflammation, cell proliferation, apoptosis, and tissue homeostasis. |
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| WINREVAIR Powder and solvent for solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) | |
| WINREVAIR Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| US | FDA, National Drug Code | 0006-5087, 0006-5088, 0006-5090, 0006-5091 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.